New Standard of Care Emerges for Multiple Myeloma

At ASCO 2025, attendees see reason for hope, despite worries

At ASCO Day 1, Summit Therapeutics crashes the party again, Pfizer's drug demonstrates "unprecedented" survival rate, and more.

New standard of care emerges for multiple myeloma

A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma, according to data presented at the annual meeting of the American Society of Clinical Oncology (ASCO), held May 30 through June 3 in Chicago.

ASCO 2025 STUDY: New Standard of Care Emerges for Multiple Myeloma

A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma. The randomized, multi-center ADVANCE clinical trial tests the effects of adding the targeted drug daratumumab to the standard three-part therapy regimen, called KRd (carfilzomib, lenalidomide and dexamethasone).

ASCO 2025 Study Unveils New Standard of Care for Multiple Myeloma

A landmark advancement in the treatment of newly diagnosed multiple myeloma patients has emerged from the recently presented ADVANCE clinical trial data, signaling a significant shift in therapeutic strategy for this blood cancer. This large, multi-center randomized study, spearheaded by the Sylvester Comprehensive Cancer Center at the University of Miami, introduces a potent four-drug regimen by incorporating the targeted immunotherapy agent da…